New clinical data validates vor bio's approach of using shielded transplants to deliver targeted therapies

Cambridge, mass., sept. 05, 2024 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing phase 1/2 vbp101 study of patients with relapsed/refractory aml receiving trem-cel followed by mylotarg™. the data demonstrated reliable engraftment, shielding from mylotarg on-target toxicity, a broadened mylotarg therapeutic window, and early evidence of patient benefit.
VOR Ratings Summary
VOR Quant Ranking